Propeller Health announced today that it has raised $20 million to support its investment in its pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease.

According to a release, Aptar Pharma led the financing round, with participation from Safeguard Scientifics, Social Capital, Hikma Ventures, 3M Ventures and SR One.

“Today marks a major step forward for our company,” Propeller Health CEO David Van Sickle said in a statement. “With our industry-leading platform and in partnership with our growing Propeller Provider Network, we now have the foundation in place to bring the benefits of digital medicines to many new conditions.”

Propeller Health also announced it will collaborate with Aptar Pharma on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The two companies will co-market the platform, with Propeller managing the digital services and Aptar Pharma managing the device development, manufacturing and supply chain.